Introduction

␥␦ T cells are unconventional T cells playing a major role in innate immune responses against microbes, stressed cells, and tumor cells. Most of circulating ␥␦ T cells use the same T-cell receptor (TCR)
V region pair V␥9-V␦2, which enables them to recognize unprocessed nonpeptide compounds, which are referred to as phosphoantigens and produced via the mevalonate or the 1-deoxy-D-xylulose-5-phosphate pathway in mammalian 1 and nonmammalian cells. 2 ␥␦ T cells also recognize induced self ligands like stress-inducible MHC class I-related MICA/MICB molecules or complexes comprising ATP-synthase subunits, which are induced or upregulated on the surface of stressed cells or some tumor cells. 3 This peculiar antigen recognition ability is the basis of the putative role of ␥␦ T cells in tumor immunosurveillance.
Aminobisphosphonates (ABP) are synthetic compounds commonly used to treat bone disease and hypercalcemia in patients with multiple myeloma and breast and prostate cancer. 4 Interestingly, ABP have also been shown to activate ␥␦ T cells in vitro and in vivo. [5] [6] [7] We and others have demonstrated that they induce the activation of ␥␦ T cells via monocytes (Mo). 6, 8 One interpretation is that ABP share the chemical features of ␥␦ T-cell ligands, but the prevailing view is that they specifically target the mevalonate pathway of Mo and induce the accumulation of phosphorylated metabolites naturally recognized by ␥␦ T cells. 6, 9, 10 Dendritic cells (DCs) are much more efficient than Mo as professional antigenpresenting cells to activate conventional ␣␤ T cells and act as cellular bridges between innate and adaptive immunity. 11 A reciprocal and positive influence has recently been described between DC and innate effector cells, including ␥␦ T cells. 11 However, whereas a few articles have investigated the effects of activated ␥␦ T cells on DCs, 12, 13 very limited data are available on the opposite interaction with special regard to the ability of DCs to modulate immune responses mediated by conventional ␣␤ T cells. To this end, we have generated highly purified immature DCs (iDCs) and mature DCs (mDCs) from peripheral blood Mo of healthy donors, and evaluated the effect of short-term incubation with zoledronic acid (Zol) on their phenotypic and functional properties. Our results demonstrate that Zol improves the immunostimulatory ability of iDC and mDC toward unconventional ␥␦ and conventional ␣␤ T cells.
Materials and methods
Blood samples were drawn from healthy donors with informed consent in accordance with the Declaration of Helsinki. The study and the consent form were approved by the Comitato Etico Regionale (Piedmont Ethical Committee).
iDC and mDC generation iDCs were generated from positively isolated CD14 ϩ cells in 18 healthy donors, as previously reported. 14 Briefly, CD14 ϩ cells were purified using CD14 MicroBeads and LS columns, according to the manufacturer's instructions (Miltenyi Biotec, Bologna, Italy; purity Ͼ 90%). The standard culture medium was RPMI 1640 (Euroclone, Milano, Italy), containing 10% fetal calf serum (Euroclone), 2 mM L-glutamine, 100 U/mL penicillin, and 100 g/mL streptomycin. CD14 ϩ cells were cultured at 2 ϫ 10 6 /mL in standard medium supplemented with 550 IU/mL recombinant human (rh) GM-CSF (Mielogen 300 Schering-Plough) and 500 IU/mL rh IL-4 (PeproTech EC Ltd, London, United Kingdom) in flat-bottomed microtiter plates (Costar, Cambridge, MA) for 6 days. Fresh cytokines were added on day 3. On day 6, the resulting cells were harvested and confirmed as iDC by morphology and immunophenotype. Contaminating CD3 ϩ and ␥␦ T cells in iDC preparations were less than 2% and 0.5% respectively, as determined by flow cytometry. iDCs were harvested on day 6 and incubated for 24 hours in the presence (iDC Zolϩ ) or absence of Zol (iDC ZolϪ ), kindly provided by Novartis Pharma, Origgio, Italy.
mDCs were generated by 24-hour stimulation of iDC ZolϪ with IL-1␤ (100 ng/mL; Alexis Biochemicals, Vinci, Italy) and TNF␣ (50 ng/mL; PeproTech, Rocky Hill, United Kingdom) in the presence (mDC Zolϩ ) or absence of Zol (mDC ZolϪ ). In some experiments, iDCs or mDCs were incubated for 24 hours in the presence of Zol and 25 M mevastatin (Mev) (Sigma-Aldrich, Milan, Italy).
iDC Zolϩ , iDC ZolϪ , mDC Zolϩ , and mDC ZolϪ were scored for cell number and viability by trypan blue staining. Supernatants were collected and stored at Ϫ80°C until cytokine contents were assessed.
Cytofluorimetric analyses
Immunophenotyping of DCs and cell subsets was performed with the following monoclonal antibodies: anti-CD3, anti-CD8, anti-CD54, anti-CD62L, anti-CXCR4 (Caltag Laboratories, Burlingame, CA), anti-pan-TCR-␥␦ (Endogen, Woburn, MA); anti-TCR-␣␤, anti-CD56, anti-CD80, anti-HLA-DR (Becton Dickinson, San Jose, CA); anti-CD3, anti-CD14 (Dako SpA, Milano, Italy); anti-V␥9TCR, anti-CD83 (BD Pharmingen International, San Diego, CA), anti-CD86 (Chemicon, Chandlers Ford, Hampshire, United Kingdom), anti-HLA-A2 (Proimmune, Oxford, United Kingdom), anti-CD1a (Valter Occhiena, Torino, Italy), anti-CD11a (Diaclone, Besancòn, France), anti-CD27 (Ancell, Byport, MN), anti-CCR7 (R&D Systems, Minneapolis, MN), and anti-DC-LAMP (Immunotech, Marseille, France). Appropriate combinations of fluorescein isothiocyanate (FITC), r-phycoerythrin-conjugated, Tri color-conjugated, or allophycocyaninconjugated antibodies were used.
Quantification of apoptotic and necrotic cells was performed by annexin V and propidium iodide staining with the MEBCYTO-Apoptosis Kit (MBL Medical and Biological Laboratories, Naka-ku Nagoya, Japan).
The internalization capability of iDC Zolϩ and iDC ZolϪ was tested using FITC-conjugated dextran (FITC-dextran; 10 Kda; Sigma-Aldrich), as previously reported. 14 Flow cytometry was conducted with a FACScan cell sorter and CELLQuest software (Becton Dickinson, Mountain View, CA). Total counts of specific cell subsets per well were determined by multiplying total counts of viable cells per well by the percentage of cells of interest, the latter being identified by 2-or 3-color cytofluorimetric analysis and appropriate gating.
Quantification of cytokine production
Quantification IL-4, IL-6, IL-10, and IL-12p70 in the supernatants of iDC Zolϩ , iDC ZolϪ , mDC Zolϩ , and mDC ZolϪ was performed with a multiparametric cytometric bead immunoassay using the Basic FlowCytomix and the Simplex kits (Bender MedSystems GmbH, Vienna, Austria). Autologous PBL were added to iDC/mDC subsets at the DC:PBL ratio of 1:5, and cultured at 1 ϫ 10 6 /mL, in standard medium supplemented with IL-2 (10 U/mL; Eurocetus, Milan, Italy). After 7 days, percentages and total counts of ␣␤ and ␥␦ T cells were determined by flow cytometry. Side-by-side experiments were also performed to compare Zol-treated Mo (Mo Zolϩ ) with iDC Zolϩ and mDC Zolϩ . To this end, CD14 ϩ were magnetically purified from cryopreserved peripheral blood mononuclear cells (PBMCs) of the individuals from whom iDC or mDC were generated, and incubated for 24 hours with Zol before mixing with autologous PBL as described.
Allostimulatory capacity of iDC
In 3 experiments, PBL were labeled with 5 M carboxy-fluorescein diacetate succinimidyl ester (CFSE; Molecular Probes, Eugene, OR), according to the manufacturer's instructions. CFSE-labeled PBL were washed once and incubated with iDC Zolϩ or mDC Zolϩ as reported. On day 7, cells were surface-stained with anti-TCR␥␦ mAb and proliferation was determined by evaluating the logarithmic decrease of CFSE fluorescence intensity after gating on ␥␦ T cells.
Modulation of adaptive immune responses
iDCs were generated from CD14 ϩ cells of HLA-A*0201 ϩ healthy donors and pulsed with the HLA-A*0201 ϩ restricted influenza matrix protein-derived peptide GILGFVFTL (MP; Proimmune, Oxford, United Kingdom) at 10 M final concentration for 2 hours at room temperature in serum-free medium (iDC MPϩ ). 15 After washing, aliquots of iDC MPϩ or unpulsed iDC (iDC MPϪ ) were induced to fully mature by incubation for 18 hours with TNF␣ ϩ IL-1␤ in the presence or absence of 5 M Zol. Thus, 4 subsets of mDC were available on day 7: mDC MPϪZolϪ , mDC MPϩZolϪ , mDC MPϪZolϩ , and mDC MPϩZolϩ . On the same day, CD3 ϩ cells were isolated from autologous cryopreserved PBMCs (Miltenyi Pan T Cell Isolation Kit), according to the manufacturer's instructions. Purity of CD3 ϩ cells (always Ͼ 90%) and percentages of ␥␦ T cells were determined by flow cytometry. mDC subsets and autologous T cells were incubated for 10 days at the DC:T ratio of 1:10 in 96-well round-bottom plates, in the presence of 10 IU/mL IL-2, which was replenished every 3 days. On day 10, T cells were restimulated for additional 10 days with a second batch of freshly generated appropriate mDC subset.
On days 10 and 20, the frequency of MP-specific CD8 ϩ T cells was determined by flow cytometry with the r-phycoerythrin-labeled A*0201/ GILGFVFTL (MP) Pentamer (Proimmune, Oxford, United Kingdom), according to manufacturers' instructions.
On day 20, the cytotoxic activity of T cells generated by 2 rounds of stimulation with mDC MPϪZolϪ , mDC MPϩZolϪ , mDC MPϪZolϩ , or mDC MPϩZolϩ was tested against the TAP-deficient HLA-A2 ϩ T2 cell line. This cell line is susceptible to the cytotoxic activity mediated by ␥␦ T cells, as shown by preliminary experiments using PBMCs stimulated for 7 days with Zol plus IL-2. 6 Both MP-loaded (T2 MPϩ ) and unloaded (T2 MPϪ ) T2 cells were used as target cells. The former served as target cells for MP-specific, MHC-restricted, conventional cytotoxic ␣␤ T cells, whereas both T2 MPϩ and T2 MPϪ cells served as target cells for cytotoxic ␥␦ T cells, which are neither MP-specific nor MHC-restricted. The cytotoxic activity of ␥␦ and ␣␤ T cells was evaluated by flow cytometry based on CFSE staining of T2 MPϩ and T2 MPϪ target cells and identification of dead cells by propidium iodide staining of CFSElabeled target cells as previously reported. 6, 16 This method works as a single-platform assay and does not require cell counting to determine the percentage of killed cells in each well. 16 In 2 experiments, T2 MPϩ cells were incubated with anti-MHC class I A*0201 antibody for 30 minutes at 4°C before washing and mixing with effector cells as reported above.
Statistical analysis
Results are expressed as mean Ϯ SEM. Differences between sample groups were evaluated with the 2-tailed nonparametric Mann-Whitney U test for paired samples or with Fisher exact test for unpaired data. P Ͻ .05 was the significance cut-off.
Results
Viability, phenotype, and function of iDC Zol؉ and mDC Zol؉ are preserved
The first series of experiments were aimed at determining any toxic effect of short-term incubation with Zol on viability, phenotype, and basic immunostimulatory functions of iDC and mDC.
Exposure to Zol up to 10 M for 72 hours did not affect the viability and total cell counts of iDC ( Figure 1A ). Based on these and previous results, 6 5 M Zol was selected as the standard treatment concentration. Zol alone did not induce any significant change in the immunophenotype of iDC (Table 1) . Rather, a significant increase in the expression of HLA-DR and CD80 was observed in mDC matured with TNF-␣ plus IL-1␤ and Zol (mDC Zolϩ ) versus TNF-␣ plus IL-1␤ alone (mDC ZolϪ ) ( Table 1) .
The ability of iDC to internalize FITC-dextran was not affected, confirming that Zol alone is unable to induce the maturation of iDC ( Figure 1B ). As expected, mDC downregulated their ability to internalize FITC-dextran, and this downregulation was unaffected by Zol ( Figure 1B ), indicating that mDC can fully mature and maintain this status in the presence of Zol.
The allostimulatory capacity of iDC Zolϩ and mDC Zolϩ was slightly increased compared with iDC ZolϪ and mDC ZolϪ , even if the differences were not statistically different ( Figure 1C ).
The release of IL-6, IL-10, IL-4, and IL-12 in the supernatants by iDC Zolϩ and mDC Zolϩ is shown in Figure 1D . IL-10 production was decreased in iDC Zolϩ , whereas IL-12 was increased, and IL-6 decreased, in mDC Zolϩ . None of these differences was statistically significant. More importantly, these changes did not invalidate the intrinsic ability of iDCs and mDCs to drive Th1 immune responses, as shown by the results of pentamer and cytotoxic experiments reported ( Figure 5A-C) .
Altogether, these data indicate that Zol has no toxic effect and does not hamper the basic phenotype and immunostimulatory functions of iDC and mDC. Figure 2B ). When the comparison was restricted to side-by-side experiments (n ϭ 4), iDC Zolϩ and mDC Zolϩ were confirmed to act as better inducers than Mo Zolϩ , although the differences were not statistically significant.
Total counts of viable ␣␤ T cells were unaffected by the proliferative expansion of ␥␦ T cells ( Figure 2B ), indicating that neither a shortage of nutrients nor the production of cytokines, such as IFN-␥, or the expansion of ␥␦ T cells with effector activity had a detrimental effect on conventional ␣␤ T cells. Total ␥␦ and ␣␤ T-cell counts also indicate that the former only accounted for the increased overall cellularity observed after stimulation with iDC Zolϩ , mDC Zolϩ , and Mo Zolϩ ( Figure 2B ), further confirming that active proliferation, and not a relative enrichment, was the main cause of the selective ␥␦ T-cell expansion. Experiments with CFSE-labeled T cells confirmed the selective proliferation of ␥␦ T cells induced by iDC Zolϩ and mDC Zolϩ ( Figure S1 , available on the Blood website; see the Supplemental Materials link at the top of the online article).
To further demonstrate the ability of Zol to specifically recruit ␥␦ T cells, iDC were incubated with 25 M Mev immediately before treatment with Zol. iDC ZolϩMevϩ were then incubated with autologous T cells and total counts of ␥␦ and ␣␤ T cells determined on day 7. The increase of ␥␦ T cells induced by iDC Zolϩ was blunted by Mev treatment (Figure 3 ). Mev treatment did not affect ␣␤ T-cell counts. These data further confirm that the immunostimulatory ability of iDC Zolϩ and mDC Zolϩ is specifically directed toward ␥␦ T cells and highly dependent on the mevalonate pathway.
Zol-treated iDCs and mDCs preferentially induce the expansion of central memory and effector memory ␥␦ T cells with enhanced expression of specific homing and costimulatory receptors
These experiments were performed to determine ␥␦ T-cell subset distribution after stimulation with iDC Zolϩ and mDC Zolϩ . ␥␦ T cells IL-10 production was decreased in iDC Zolϩ , whereas IL-12 was increased and IL-6 was decreased in mDC Zolϩ . None of these differences reached a statistical significance.
. Naive (N: CD45RA ϩ , CD27 ϩ ) and central memory (CM: CD45RA Ϫ , CD27 ϩ ) ␥␦ T cells display high proliferative capacity, but low effector functions, whereas effector memory (EM: CD45RA Ϫ , CD27 Ϫ ) and terminally differentiated late effector (TEMRA: CD45RA ϩ , CD27 Ϫ ) ␥␦ T cells display the opposite pattern. 17 Immunophenotyping on day 7 showed that total counts of viable CM and EM ␥␦ T cells per well were significantly increased after stimulation with iDC Zolϩ compared with iDC ZolϪ (Figure 4A,B) .
iDC Zolϩ and mDC Zolϩ stimulation also increased the number of ␥␦ T cells with appropriate cell surface receptors to target secondary lymphoid organs (CD62L) 17 and exert costimulatory activity (HLA-DR, CD80) 18 ( Figure 4C,D) .
Ag-specific immune responses mediated by ␣␤ T lymphocytes are improved by the concurrent activation of ␥␦ T cells
The last series of experiments was carried out to determine whether Zol treatment was beneficial or detrimental to the ability of mDC to generate Ag-specific immune responses mediated by conventional ␣␤ T cells.
First, we evaluated the frequency of A*0201-restricted MPspecific CD8 ϩ ␣␤ T cells after stimulation with mDC MPϪZolϪ , mDC MPϩZolϪ , mDC MPϪZolϩ , and mDC MPϩZolϩ . The highest frequency was observed after stimulation with mDC MPϩZolϩ , both after the first (day 10; Figure 5A ) and the second round (day 20) of stimulation (one additional experiment is shown in Figure S2 ).
Next, we tested the ability of effector T cells generated by 2 rounds of stimulation to exert cytotoxic activity against T2 MPϩ or T2 MPϪ cells. Results are shown in Figure 5B . mDC MPϪZolϪ did not induce any cytotoxic activity against T2 MPϩ or T2 MPϪ cells. As expected, mDC MPϩZolϪ generated MP-specific cytotoxic responses against T2 MPϩ cells only, mediated by conventional CD8 ϩ ␣␤ T cells, but did not induce the expansion of ␥␦ T cells. mDC MPϪZolϩ induced the expansion of ␥␦ T cells and generated comparable responses against both T2 MPϩ and T2 MPϪ cells, indicating lack of MHC restriction and MP specificity. Interestingly, the cytotoxic activity mediated by CD8 ϩ ␣␤ T cells against T2 MPϩ cells was significantly increased after stimulation with DC MPϩZolϩ compared with that observed in the absence of ␥␦ T-cell expansion (ie, after activation by mDC MP ϩ ZolϪ ; effector target [E/T] ratio 1,3:1; Results are mean fluorescence intensity (MFI) plus or minus the SEM from 10 (HLA-DR) to 3 (DC-LAMP) experiments. *iDCs were generated from peripheral monocytes by incubation for 6 days with IL-4 and granulocyte-macrophage colony-stimulating factor as reported in "Materials and methods." On day 6, iDCs were harvested and incubated for 24 hours in the presence (iDC Zolϩ ) or absence of 5 M Zol (iDC ZolϪ ).
†mDCs were generated by incubation of iDCs with TNF-␣ and IL-1␤ for 24 hours in the presence (mDC Zolϩ ) or absence (mDC ZolϪ ) of 5 M Zol. DC-LAMP expression is determined after 48 hours of incubation.
‡ Difference statistically significant between mDC ZolϪ and mDC Zolϩ (both P Ͻ .05). Figure 5C , showing that the cytotoxicity against T2 MPϩ cells was partly abrogated by anti-MHC class I antibody. Thus, MP-specific CD8 ϩ ␣␤ T cells are generated under these conditions and contribute to the cytotoxic response against T2 MPϩ cells.
Figure 2. Proliferative expansion of ␥␦ T cells by iDC
In conclusion, iDC can be concurrently loaded with antigens specific for ␣␤ and ␥␦ T cells and effectively induce the activation of both subsets. The largely predominant activation of ␥␦ T cells does not overwhelm, but rather it has beneficial effects on the generation of antigen-specific cytotoxic responses mediated by ␣␤ T cells.
Discussion
The aim of this work was to determine whether short-term incubation with Zol had any impact on the immunostimulatory properties of iDC, with special regard to their ability to activate autologous ␥␦ T cells and modulate antigen-specific immune responses mediated by ␣␤ T cells. Cell count and viability of iDC as well as their subsequent differentiation into mDC, induced by TNF␣ and IL-1␤, were not affected by Zol exposure up to 10 M for 72 hours. Similar results have been reported by Wolf et al. 19 On the contrary, Zol did affect the generation of iDC, as previously shown by von Lilienfeld-Toal et al 20 and Wolf et al. 19 However, these experiments were performed with Mo incubated with Zol for 3 days during their differentiation process into iDC, and not with freshly generated iDC as in our case.
Zol alone was unable to induce iDC maturation, as shown by the very similar immunophenotype and ability of iDC ZolϪ and iDC Zolϩ to internalize FITC-dextran. The immunostimulatory phenotype of mDC Zolϩ was slightly improved, as shown by the increased cell surface HLA-DR and CD80 expression, whereas both mDC ZolϪ and mDC Zolϩ equally downregulated their ability to internalize BLOOD, 1 AUGUST 2007 ⅐ VOLUME 110, NUMBER 3 For personal use only. on April 14, 2017 . by guest www.bloodjournal.org From FITC-dextran, according to their full maturation status. Curiously, the increased HLA-DR and CD80 expression of mDC Zolϩ did not translate into an increased allostimulatory activity, as already reported by Wolf et al. 19 Last, the pattern of cytokine production by iDC Zolϩ and mDC Zolϩ was not statistically different from that of iDC ZolϪ and mDC ZolϪ , even if a trend toward a more favorable cytokine production to drive Th1 immune responses could be envisaged in mDC Zolϩ (eg, higher and lower production of IL-12 and IL-6, respectively). Altogether, these data indicate that Zol has no toxic effect and does not hamper the basic phenotype and immunostimulatory functions of iDCs and mDCs.
Previous reports have shown that exogenous phosphoantigens, like isopentenyl pyrophosphate and bromohydrin pyrophosphate, mimic the natural ligands of ␥␦ T cells and do not induce any phenotypic change or cytokine modulation in iDCs. 12, 20, 21 However, phosphoantigens and ABP act by very different mechanisms. The former mimic the natural ligands of ␥␦ T cells and are not internalized by iDCs or mDCs, whereas ABP target the intracellular mevalonate pathway by blocking the farnesyl pyrophosphate synthase. Among ABP, Zol is approximately 100-fold more potent than pamidronate in blocking the farnesyl pyrophosphate synthase. 22 Thus, it is not surprising that ABP induce a deeper immunomodulation than exogenously added phosphoantigens, nor that Zol is more active than pamidronate.
Next, we have evaluated the ability of iDC Zolϩ and mDC Zolϩ to activate autologous ␥␦ T cells. So far, very few studies have investigated the ability of highly purified iDCs and mDCs to activate such cells after treatment with phosphoantigens or ABP. We used resting autologous PBL or purified T cells as a source of ␥␦ T cells rather than ␥␦ T-cell clones or purified ␥␦ T cells, because we wished to investigate both the reciprocal interaction between DCs and ␥␦ T cells, and its effect on the ability of DCs to induce antigen-specific immune responses mediated by conventional ␣␤ T cells. iDC Zolϩ and mDC Zolϩ very efficiently induced the proliferative expansion of autologous ␥␦ T cells. Zol was the main cause of ␥␦ T-cell activation because: (1) iDC ZolϪ and mDC ZolϪ were totally ineffective; (2) iDC and mDC subsets were extensively washed before adding autologous PBL or purified T cells; (3) both PBL and T cells were devoid of CD14 ϩ cells potentially targetable by residual Zol, if any; and (4) the immunostimulatory ability of iDC Zolϩ and mDC Zolϩ was abrogated by Mev, indicating that targeting the mevalonate pathway of iDC and mDC is an essential prerequisite to recruit ␥␦ T cells, as previously reported in Mo and tumor cells. 6, 9, 10 So far, only von Lilienfeld-Toal et al 20 have investigated and failed to show that ABP-treated iDCs induce the proliferation of ␥␦ T cells. However, these experiments were performed with positively selected ␥␦ T cells, fully activated by anti-CD3 mAb and high doses of IL-2 and IL-1␤, and proliferation was evaluated 3 days only after coculturing with iDC. Given the strong ␥␦ T-cell baseline activation status and the short incubation time, it is not surprising that ABP-treatment of iDC did not significantly affect the proliferation of ␥␦ T cells. Devilder et al 13 did not observe any proliferation after incubation of ␥␦ T-cell clones with iDC or mDC in the presence of bromohydrin pyrophosphate. These results further confirm the inferiority of phosphoantigens to ABP in the ability to specifically prime DCs to induce ␥␦ T-cell activation.
iDC Zolϩ were slightly better than mDC Zolϩ , and both subsets were better than Mo Zolϩ in inducing the expansion of ␥␦ T cells. This is the first time that these subsets are side-by-side compared. Previous experiments were performed with PBMCs, rather than purified Mo, and cultures were never washed free of Zol. 6, 10 Devilder et al 13 have shown that pamidronate-treated iDCs are superior to mDCs in inducing the expression of intracellular TNF␣ in clonal or polyclonal ␥␦ T cells. To the best of our knowledge, this is the only other demonstration that ABP specifically prime iDCs and mDCs to activate ␥␦ T cells.
The vigorous ␥␦ T-cell expansion induced by iDC Zolϩ and mDC Zolϩ indicates that this strategy is worthy of further investigation as a platform for adoptive cell therapy. It has recently become clear that the successful outcome of adoptive cell therapy very much depends on the differentiation status of the cells infused. CM T cells have more effective antitumor activity in vivo than EM or TEMRA T cells, even though the latter are more potent in vitro. 23, 24 These data have been validated in vivo with CD8 ϩ cells only, but recent findings indicate that ␥␦ T cells, too, can be subdivided in the same subsets (N, CM, EM, TEMRA) with similar phenotypic and functional properties. 6, 17 Indeed, iDC Zolϩ preferentially induced the expansion of CM and EM ␥␦ T cells, which are well-fitted to exert antitumor activity, as shown by their cytotoxic activity against the T2 cell line and other tumor cell lines, as previously reported. 6 iDC Zolϩ and mDC Zolϩ induced the expansion of ␥␦ T cells expressing homing receptors for secondary lymphoid organs (CD62L ϩ ) and costimulatory molecules (HLA-DR ϩ , CD80 ϩ ). The former are especially expressed at the stage of CM cells 25 and enable ␥␦ T cells to migrate to lymph nodes where they interact with DC and other cells to improve the outcome of adaptive immune responses. The expression of costimulatory molecules has been related to the capacity of ␥␦ T cells to act as APC themselves, 18 even if these data are controversial and we were not able to confirm the endocytic function of activated ␥␦ T cells. Whether ␥␦ T cells can act as antigen-presenting cells, the phenotype expressed by activated ␥␦ T cells, the well-preserved immunostimulatory functions of iDC Zolϩ and mDC Zolϩ , and the preserved numbers of conventional ␣␤ T cells prompted us to investigate whether iDC could be primed with the appropriate antigens to simultaneously activate both ␣␤ and ␥␦ T cells. To gain insights into this issue, we pulsed iDCs with MP in the presence or absence of Zol and then induced their differentiation into mDC with TNF-␣ ϩ IL-1␤. Then, we determined the frequency of MP-specific CD8 ϩ T cells and cytotoxic responses against T2 MPϩ and T2 MPϪ cells. Notably, the highest frequency of MP-specific CD8 ϩ ␣␤ T cells and the highest cytotoxicity against T2 MPϩ cells were observed after stimulation with mDC MPϩZolϩ . These results indicate that iDC can be concurrently loaded with antigens specific for ␣␤ and ␥␦ T cells and effectively induce the activation of both subsets. The largely predominant activation of ␥␦ T cells has beneficial effects on the generation of MP-specific CD8 ϩ ␣␤ T cells as shown by the higher frequency of MP-specific CD8 ϩ ␣␤ T cells and higher cytotoxic activity against T2 MPϩ cells detected after stimulation with mDC MPϩZolϩ compared with mDC MPϩZolϪ . Blocking experiments with anti-MHC class I antibody also indicate that: (1) MP-specific CD8 ϩ ␣␤ T cells are generated after stimulation with mDC MPϩZolϩ ; (2) these cells are not overwhelmed by the much more abundant activated ␥␦ T cells; and (3) they contribute to the bulk cytotoxic activity detected against T2 MPϩ cells.
The generation of MHC-restricted antigen-specific cytotoxic ␣␤ T cells seemed to draw more benefit from the concurrent ␥␦ T-cell activation than vice versa, as shown by the similar cytotoxic activity against T2 MPϪ cells induced by mDC MPϩZolϩ and mDC MPϪZolϩ . Given the very different frequencies, it is not surprising that the much more abundant activated ␥␦ T cells improve the efficiency of the much less represented MHCrestricted antigen-specific ␣␤ T cells. This is the first report in humans showing that iDCs can be simultaneously primed to activate both ␥␦ and ␣␤ T cells, and that the former act as cellular adjuvants for the development of adaptive immune responses. These data further support the notion that ␥␦ T cells are endowed with more sophisticated functions than simply providing a first-line defense against pathogens or self-induced stress antigens in the peripheral tissues. Mouse models have confirmed that ␥␦ T cells do provide help to adaptive immune responses by promoting the formation of germinal centers, the somatic hypermutation of B cells, 26 and by positively regulating superantigen-specific immune responses mediated by ␣␤ T cells. 27 In conclusion, our results indicate that it is possible to quickly generate large numbers of activated ␥␦ T cells with effector and costimulatory activities by short-term incubation with iDCs/mDCs pulsed with the appropriate antigens. This strategy is worthy of further investigation to improve adoptive cell therapy and vaccine interventions against tumors and infections.
